Drug intelligence / Profile preview

forsythoside I

Development stage: Preclinical
Lead developer: Beijing An Zhen Hospital
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Forsythoside I is a phenylethanoid glycoside, likely derived from the medicinal plant *Forsythia suspensa*, that acts as a small molecule agonist of the small GTPase **RAC1**. Research presented at the AHA 2025 meeting identifies it as a potential therapeutic for **aortic aneurysm and dissection (AAD)**. The compound specifically binds to the Q61 site of RAC1, promoting its activity and counteracting the inhibitory effects of elevated MST1 expression. By restoring RAC1 activation and subsequent FLNB-mediated vascular smooth muscle cell contractility, Forsythoside I has demonstrated significant therapeutic efficacy and a high safety profile in preclinical animal models of AAD.

Other names: forsythoside I

Targets

RAC1 (Rac family small GTPase 1)

Beyond the preview

Go deeper on forsythoside I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on forsythoside I.

Explore the full profile